Results 141 to 150 of about 3,065,508 (250)

VEGF‐A Antisense Oligonucleotide Therapy Inhibits Corneal Neovascularisation and Enhances Graft Survival in Murine High‐Risk Corneal Transplantation

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To investigate, for the first time, whether an unconjugated VEGF‐A antisense oligonucleotide (ASO) can inhibit corneal neovascularisation and improve graft survival in a murine high‐risk corneal transplantation model. Methods A suture‐induced corneal neovascularisation model was established in BALB/c mice, followed by high‐risk ...
Wei Zhang, Christian Weile, Christoph Ullmer, Sascha Fauser, Felix Bock, Claus Cursiefen   +5 more
wiley   +1 more source

Means and methods for ocular drug delivery

, 2015
The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue.
Vries, Jan Willem de, Herrmann, Andreas, Spitzer, Martin Stephan, Schnichels, Sven Oliver   +3 more
core   +2 more sources

Flexible polymeric nanosized micelles for ophthalmic drug delivery: research progress in the last three years. [PDF]

Nanoscale Adv, 2021
Li Z, Liu M, Ke L, Wang LJ, Wu C, Li C, Li Z, Wu YL.   +7 more
europepmc   +1 more source

Evaluation of the Safety and Therapeutic Range of Nanosecond Laser Treatment in Rabbits

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Subthreshold, nanosecond laser therapy has potential as a treatment for age‐related macular degeneration; however, the therapeutic range and safety profile have not been fully documented. In this study, rabbits were used for a preclinical assessment of nanosecond laser treatment.
Glyn Chidlow, John P. M. Wood, Weng Onn Chan, Robert J. Casson   +3 more
wiley   +1 more source

Advancements in materials and fabrication techniques for microneedle ocular patch: a comprehensive review

Discover Applied Sciences
With the increasing prevalence of ocular diseases, there is an urgent need to look beyond conventional formulations, such as eye drops, ointments, and intravitreal injections, to treat various ocular diseases.
Karishma Sharma, Aiswarya Ramachandran, Venkata Vamsi Krishna Venuganti, Vishal Raval   +3 more
doaj   +1 more source

A New Case of Lethal Congenital Contracture Syndrome Type 3 With Hyperinsulinism and Optic Atrophy

Clinical Genetics, EarlyView.
PIP5K1C‐related lethal congenital contracture syndrome with hyperinsulinism and optic atrophy. ABSTRACT Lethal congenital contracture syndrome 3 (LCCS3, MIM #611369) is a rare autosomal recessive neuromuscular disorder caused by biallelic loss‐of‐function (LOF) variants in PIP5K1C, reported in only two families to date.
Tameemi Abdalla Moady, Hadar Hulin Ma'ayan, Michal Cohen, Karin Weiss   +3 more
wiley   +1 more source

Preclinical Evaluations of Modified Rice Hydrogel for Topical Ophthalmic Drug Delivery of Praziquantel on Avian Philophalmiasis. [PDF]

Pharmaceutics, 2021
Prompetch T, Chailorm A, Tiwananthagorn S, Buranapim N, Okonogi S, Kato H, Katip W, Mektrirat R.   +7 more
europepmc   +1 more source

Innovations in Nanoemulsion Technology: Enhancing Drug Delivery for Oral, Parenteral, and Ophthalmic Applications

Pharmaceutics
Nanoemulsions (NEs) are submicron-sized heterogeneous biphasic liquid systems stabilized by surfactants. They are physically transparent or translucent, optically isotropic, and kinetically stable, with droplet sizes ranging from 20 to 500 nm.
Shery Jacob, Fathima Sheik Kather, Sai H. S. Boddu, Jigar Shah, Anroop B. Nair   +4 more
doaj   +1 more source

Macrophage Lipid Homeostasis Drives IVDD via a Senescence‐Dependent Impairment of Efferocytosis

Cell Proliferation, EarlyView.
Intervertebral disc degeneration (IVDD) has been a leading cause of low back pain and lacks disease‐modifying therapies. Although dysregulated disc lipid metabolism is implicated, its impact on the immune microenvironment, particularly macrophages, remains unknown.
Jinyu Wang, Shiyong Ling, Qi Wang, Xuege Qiao, Jianpeng Xing, Siyang Ji, Linhui Han, Chen Yan, Zhishen Niu, Lei Yuan, Baolian Zhao, Kaiqiang Sun, Jiangang Shi   +12 more
wiley   +1 more source

Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review

Haemophilia, EarlyView.
ABSTRACT Introduction Perioperative management in haemophilia often requires on‐demand use of clotting factor concentrates (CFC) and/or bypassing agents. Rebalancing agents (fitusiran, concizumab, marstacimab) offer a novel approach to prophylaxis by modulating endogenous anticoagulant pathways to restore haemostatic balance.
Amanda M. Henderson, Roy Khalife, Kelsey Uminski   +2 more
wiley   +1 more source